AzTrials
AzTrials

ImplantNCT07187609

Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in Immediately Placed Implant

A study testing Immediate implant with bovine drived hydroxyapatite xenograft. and immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft in people with Implant and Zinc Status, run by Suez Canal University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate Clinical and radiographic effect of zinc incorporated bovine derived hydroxyapatite xenograft and bovine hydroxyapatite xenograft alone for immediately placed implant Read more about this study

Who is it for?
Ages 30 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Implant, Zinc Status
What is being tested?
Immediate implant with bovine drived hydroxyapatite xenograft. and immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
1 siteEgypt
Study dates
13 Aug 2025to 8 Oct 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adult(male or female) patients between the ages of 30 - 55 years who requiring the replacement of one or more non-restorable teeth in the mandible which will be indicated for extraction.
  • Adequate bone dimensions at the implant site with ridge width of at least 6 mm, the availability of at least 3mm of sound subapical bone, the presence of an intact labial bone plate, and no evidance of periapical infection on cone beam computed tomography or clinically
  • The peri-implant gaps larger than 1.5 mm will be included.
  • All patients will be physically healthy with no medical history of any systemic disease.

Who cannot join

  • Smokers.
  • Patients with para functional habits such as bruxism and clenching
  • Poorly controlled systemic diseases which preclude local anesthesia or surgical procedures
  • Patients undergoing chemotherapy or radiotherapy and immuno-compromised patients.
  • Pregnant /lactating women.
  • Patients that are allergic to zinc
  • Patients on antibiotic therapy in the pervious 6 months

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Suez canal university

    Suez

Other trials in Egypt

About this study

Official title: Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in the Jumping Gap of Immediately Placed Implant: A Randomized Clinical Study

The aim of this study is to evaluate Clinical and radiographic effect of zinc incorporated bovine derived hydroxyapatite xenograft and bovine hydroxyapatite xenograft alone for immediately placed implant

Read the detailed description

Implant dentistry is a prosthetic effort via a surgical procedure. In order to achieve an ideal prosthetic construct, precise plan should be taken into consideration prior to the beginning of treatment. The position of implant requires protected prosthesis. It can be affected by the implant size, volume, and the quantity and quality of bone provided at various sites.

One pitfall of immediate implant use, however, is the inevitable residual space that remains between the implant body and the socket wall, due to a discrepancy in size between the implant and the socket wall. This space, which is located toward the coronal end of the implant, is called the jumping distance. Excessive jumping distance may lead to bone resorption and formation of a bony defect, decreasing the implant stability .

One of the most extensively used methods for restoration of the lost attachment is the use of bone grafts. bone grafting which is one of the methods used to address these issues has experienced an increased level of demand.

The problem of bone defects has also contributed to making bone autograft become the gold standard for treating bone abnormalities, although it has its limitations which are graft quantity and donor site morbidity. Contributory,allografts have become popular for replacing bone defects because the graft size can be easily adjusted but it also has several drawbacks, including disease transfer, rejection reactions, non-union, graft resorption, fracture, and donor restrictions A xenograft is one of the choices used to overcome these limitations since the raw material is plentiful, readily available, and inexpensive. Additionally, several previous studies showed that organic or inorganic matrix derived from bovine bone is biocompatible, but this biomaterial requires proper preparation to avoid risks such as the transmission of zoonoses .

Bovine hydroxyapatite is made up of materials which have biological properties that makes it biocompatible and osteoconductive. These important biological properties allow the apposition of newly formed bone by osteoprogenitor cells and the partial remodeling by osteoclast and osteoblast of the host . Hydroxyapatite is used as scaffolds to support the development of bone tissue from an osteoblast proliferation stage through to extracellular matrix (ECM) deposition and on to cell-mediated early-stage mineralization. The addition of small quantities of hydroxyapatite to the scaffolds considerably increases calcium deposition and has a mild osteogenic impact.

One of the potential methods for producing anorganic xenograft with enhanced osteoconductivity is by substituting ions with the constituent elements of hydroxyapatite that exist in bone mineral because this method has the potential to increase hydroxyapatite solubility by lowering its crystallinity and inducing a higher number of structural defects. For these reasons, the ionic activity product of apatite increases in body fluid due to the released constituent elements of apatite and this will provoke the formation of low crystalline hydroxyl carbonate apatite (bioactivity) on ions substituted hydroxyapatite surface, which enhances osteoconductivity. However, the effect of other ions in bone on the bioactivity and osteoconductivity of hydroxyapatite has not been extensively investigated. The substitutions of sodium with calcium ions and chlorine with hydroxyl ions in hydroxyapatite have been also reported, respectively, but they were confined to synthetic procedures and structural analyses.

Zinc is the most abundant trace metallic element found in the body with 85% present in muscle and bone. Zinc has proven to possess a direct stimulatory effect on osteoblastic cells in vitro while bone resorption was inhibited . It also reduces bacterial load, thus proving its antimicrobial properties. Many studies have demonstrated that zinc significantly improved the bioactivity of HA. Therefore, zinc-HA can be a new generation of materials for bone tissue- engineering.

In comparison with the pure HA group, Zn2+-doped HA had more connective tissues replaced by rebuilt bones, confirming that Zn2+-doped HA had a stronger osteo-induction potential.

In a word, Zn2+ ions act in promoting cell proliferation, increasing osteogenic activity, and inhibiting osteoclast bioactivity. Zn2+-doped HA was considered as a suitable substitute for cancellous bone.

To the best of our knowledge there are no studies conducted on zinc incorporation bovine derived hydroxyapatite xenograft (Zn-BHA) on immediate implant so this study designed to evaluate the effect of bovine drived hydroxyapatite xenograft (BHA) alone and zinc incorporated bovine drived hydroxyapatite xenograft clinically and radographically on immediat implant.

With the advancement of computer-aided design and computer-aided manufacturing (CAD-CAM) technology, there are different approaches for implant prosthetics' digital workflow.

Recent digital technology allowed the virtual extraction of unrestorable teeth, the design of a restoration with a perfect emergence profile that preserves soft tissue contour, and finally the 3D printing of the interim restoration.

The CAD-CAM guided templates have many applications in dentistry such as implant placement and endodontic access preparations, the guided implant osteotomy presents an accurate protocol for implant placement in the preplanned position with less surgical time and few post-surgical complications.

The digitally designed surgical guides transfer the virtually planned implant angulation, width and length through the use of 3D printed transparent template.

Conditions
Implant, Zinc Status
Being tested
Immediate implant with bovine drived hydroxyapatite xenograft., immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
Keywords
bone grafts, Implant, zinc in corporated bovine drived hydroxyappatite

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Immediate implant with bovine drived hydroxyapatite xenograft.Procedure or surgery

    patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.

  • immediate implant with zinc incorporated bovine drived hydroxyapatite xenograftProcedure or surgery

    patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

Study groups in NCT07187609
Study groupRoleWhat they receive
Group I (control)Experimentalpatients will undergo immediate implant with bovine drived hydroxyapatite xenograft
Receives: Procedure: Immediate implant with bovine drived hydroxyapatite xenograft.
Group II (Test group)Experimentalpatients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
Receives: Procedure: immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Marginal bone loss

    Marginal bone loss was defined as the distance from the implant platform to the alveolar crest.

    Measured: 9 months

Secondary outcomes (1)
  1. densitometric gray scale value to measure bone density

    Measured: 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2025
  2. Study start13 Aug 2025
  3. Primary completion8 Oct 2026
  4. Study completion8 Oct 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07187609
Sponsor's protocol ID
Zinc in immediate implant
Status last verified
Sep 2024
First submitted
16 Aug 2025
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Immediate implant with bovine drived hydroxyapatite xenograft. and immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft in people with Implant and Zinc Status, run by Suez Canal University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Marginal bone loss (time frame: 9 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in